Go to Page # Page of 45

The Epicutaneous Immunotherapy Company

 DBV Technologies
  7th-Mar-2018
Description: This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBVs clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to successfully advance its pipeline of product candidates; the rate and degree of market acceptance of its products; and its ability to develop sales and marketing capabilities.
Views: 1193
Domain: Medical
Category: Therapy
Contributing Organization: DBV Technologies
 ‐ More of their Presentations
SEMICONDUCTOR ANALYTICS
Contents:
The Epicutaneous
Immunotherapy
Company
©Genoskin

January 2018

Safe Harbor
This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or
success of DBV’s clinical trials; its ability to successfully gain regulatory approvals and commercialize products; its ability to
successfully advance its pipeline of product candidates; th ... See more

The Epicutaneous Immunotherapy Company

This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success of DBVs clinical trials; its ability to successfu

DBV Technologies
08 May, 2018